logo
Share SHARE
FONT-SIZE Plus   Neg

Great Wolf, Apollo Agree On Increased Offer Price Of $6.75 Per Share

K-9 Acquisition, Inc., an affiliate of Apollo Global Management (APO), and Great Wolf Resorts, Inc. (WOLF) said Friday that they have entered into an amended merger agreement, whereby Apollo has agreed to increase its offer to acquire Great Wolf from $5.00 per share in cash to $6.75 per share in cash.

The increased offer price represents a premium of 61% over Great Wolf's closing stock price on the day prior to the announcement of the original offer on March 12 and a premium of 3% over the company's closing stock price on Thursday, April 5.

The increased offer was unanimously approved by the Great Wolf board of directors. The board has determined to recommend that Great Wolf shareholders tender their shares into Apollo's revised tender offer, which will expire on April 20.

In connection with the increased offer, Great Wolf has agreed to increase the termination fee and expense reimbursement payable to Apollo in certain circumstances, in proportion to the increase in the offer price, from a total of up to $7 million to a total of up to $9 million.

Additionally, Great Wolf said its board has terminated its consideration and evaluation of the April 4 unsolicited proposal from KSL Capital Partners to buy Great Wolf for $6.25 per share in cash.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT